ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface receptor tyrosine kinase, as a tractable molecular target in neuroblastoma. We describe comprehensive genomic, biochemical, and computational analyses of ALK mutations across 1596 diagnostic neuroblastoma samples. ALK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Bresler, Scott C., Weiser, Daniel A., Huwe, Peter J., Park, Jin H., Krytska, Kateryna, Ryles, Hannah, Laudenslager, Marci, Rappaport, Eric F., Wood, Andrew C., McGrady, Patrick W., Hogarty, Michael D., London, Wendy B., Radhakrishnan, Ravi, Lemmon, Mark A., Mossé, Yaël P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4269829/
https://ncbi.nlm.nih.gov/pubmed/25517749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2014.09.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados